Item 1(a). | Name of Issuer: |
Senti Biosciences, Inc. (the “Issuer”)
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
2 Corporate Drive, First Floor
South San Francisco, CA 94080
Item 2(a). | Name of Person Filing: |
This joint statement on Schedule 13G is being filed by 8VC Fund I, L.P. (“8VC Fund I”), 8VC Entrepreneurs Fund I, L.P. (“Entrepreneurs I”) and 8VC GP I, LLC (“8VC GP I” together with 8VC Fund I and Entrepreneurs I, the “Reporting Entities”) and Joe Lonsdale (“Lonsdale” together with the Reporting Entities, the “Reporting Persons”) Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.
Item 2(b) | Address of Principal Business Office, or if None, Residence: |
The address of the principal business office of the Reporting Persons is: 907 South Congress Avenue, Austin, TX 78704.
8VC GP I is a limited liability company organized under the laws of the State of Delaware. Each of 8VC Fund I and Entrepreneurs I is a limited partnership organized under the laws of the State of Delaware. Lonsdale is a citizen of the United States of America.
Item 2(d). | Title of Class of Securities: |
Common Stock, $0.0001 par value per share (“Common Stock”).
81726A100
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
| (a) | Amount beneficially owned: |
See Row 9 of the cover page for each Reporting Person and the corresponding footnotes.*
See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*
| (c) | Number of shares as to which the person has: |
| (i) | Sole power to vote or to direct the vote |
See Row 5 of the cover page for each Reporting Person and the corresponding footnotes.*
| (ii) | Shared power to vote or to direct the vote |